Alexander Burik, Author at Labiotech.eu

About

Born in Chicago, I grew up close to Frankfurt, Germany. I hold an MSc in Neuroscience from University College London and a BA in Biochemistry from Knox College in the US.
Outside of science-related activities, I enjoy skiing and writing music.

Articles by Alexander Burik

News and Trends 2 Jul 2018

Dutch Snake Venom-Derived Clotting Agent Comes Closer to the Clinic

Dutch biotech raises €12.5M to complete the preclinical development of its lead compound for acute internal bleeding and bring the drug into clinical trials. VarmX, based in Leiden, the Netherlands, raised a Series A round of €7.5M led by BioGeneration Ventures, with an additional €5M provided by the Netherlands Enterprise Agency as an Innovation Credit. The […]

July 2, 2018 - 1 minutemin - By Alexander Burik

Startup Scout 29 Jun 2018

This French Biotech Links Drugs Together to Target Bone Cancer

This week, we’re in Aronnax, France, visiting Atlanthera, a biotech developing more effective treatments for bone cancer using a two-compound approach. Mission: Antlanthera was founded in 2011 with the goal of developing more effective drugs for bone cancer. The company uses biophosphonates, a popular bone-building treatment for osteoporosis, to target bone tissue. Atlanthera’s technology works […]

June 29, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

A Biodegradable Plaster Could Help us Treat Mouth Ulcers

British researchers and a Danish biotech have joined forces to develop a polymer patch that can treat mouth ulcer patients with long-term steroid release and make the wound-healing process faster. Dermtreat, based in Copenhagen, and researchers from the University of Sheffield’s School of Clinical Dentistry in the UK made a patch from polymers that stick […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […]

June 25, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Jun 2018

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […]

June 25, 2018 - 3 minutesmins - By Alexander Burik

Interview 22 Jun 2018

Swedish Biotech’s Liquid Biopsy Could Improve Accuracy of Cancer Diagnoses

Elypta is developing liquid biopsies that analyze cancer metabolism to make cancer diagnoses more accurate. Philip talked to Francesco Gatto, Elypta’s Chief Scientific Officer and a co-founder, on their technology, moving from academia to industry, and the challenges of starting a biotech company. Even though biotechs and pharma companies across the globe have been pouring […]

June 22, 2018 - 5 minutesmins - By Alexander Burik

News and Trends 21 Jun 2018

Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World

Researchers at the University of Edinburgh have genetically engineered pigs that are resistant to a common disease that has exorbitant costs to the livestock industry. Researchers at the University of Edinburgh, in collaboration with the animal genetics company Genus, have produced pigs that are resistant to one of the most costly animal diseases in the […]

June 21, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 20 Jun 2018

Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic

iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […]

June 20, 2018 - 2 minutesmins - By Alexander Burik

Interview 20 Jun 2018

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […]

June 20, 2018 - 9 minutesmins - By Alexander Burik

News and Trends 19 Jun 2018

A Chip Could Help Us Identify Wheeze-Causing Types of Viruses

Researchers in Vienna have developed a chip that identifies cold viruses that cause flare-ups of respiratory conditions such as asthma. The technology could help identify culprit viruses and help those affected take the best preventive and treatment measures. The chip, created by researchers at the Medical University of Vienna, uses a small blood sample to […]

June 19, 2018 - 2 minutesmins - By Alexander Burik

More News! 18 Jun 2018

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […]

June 18, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 Jun 2018

London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials

ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […]

June 15, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alexander Burik

About

Articles by Alexander Burik

Dutch Snake Venom-Derived Clotting Agent Comes Closer to the Clinic

This French Biotech Links Drugs Together to Target Bone Cancer

A Biodegradable Plaster Could Help us Treat Mouth Ulcers

Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation

Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers

Swedish Biotech’s Liquid Biopsy Could Improve Accuracy of Cancer Diagnoses

Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World

Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

A Chip Could Help Us Identify Wheeze-Causing Types of Viruses

Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage

London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alexander Burik

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!